Treatment outcome in a cohort of young patients with polycythemia vera

Internal and Emergency Medicine

Volumn 5, Issue 5, 2010, Pages 411-413

  Ruggeri, Marco ^a   Finotto, Silvia ^a   Fortuna, Stefania ^a   Rodeghiero, Francesco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Polycythemia vera; Therapy; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; FIBRINOLYTIC AGENT; HYDROXYUREA; JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHLEBOTOMY; POLYCYTHEMIA VERA; RETROSPECTIVE STUDY; THROMBOSIS;

ADULT; ANTINEOPLASTIC AGENTS; ASPIRIN; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYUREA; JANUS KINASE 2; MALE; MIDDLE AGED; PHLEBOTOMY; POLYCYTHEMIA VERA; RETROSPECTIVE STUDIES; THROMBOSIS; YOUNG ADULT;

EID: 77956838988     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0429-y     Document Type: Article

References (14)

1. Gruppo Italiano Studio Policitemia Polycythemia Vera (1995) The Natural history of 1213 patients followed for 20 years. Ann Intern Med 123: 656-664.
2. Najean Y, Mugnier P, Dresch C, Rain JD (1987) Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol 67: 2852-2891.
3. Frezzato M, Ruggeri M, Castaman G, Rodeghiero F (1993) Polycythemia vera and essential thrombocythemia in young patients. Haematologica 78(2): 11-17.
4. Perea G, Remacha A, Besses C, Jimenez M, Florensa L, Cervantes F (2001) Is polycythemia vera a serious disease in young adults? Haematologica 86: 543-544.
5. Passamonti F, Malabarba L, Orlandi E et al (2003) Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukaemia. Haematologica 88: 13-18.
6. Passamonti F, Rumi E, Pungolino E et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117: 755-761.
7. Finazzi G, Barbui T (2007) How I treat patients with Polycythemia Vera. Blood 109: 5104-5111.
8. Mannucci PM (2007) Polycythaemia vera and JAK2 mutation. Intern Emerg Med 2: 147.
9. Finazzi G, Barbui T (2007) The treatment of polycythaemia vera: an update in the JAK2 era. Intern Emerg Med 2: 13-18.
10. Pardanani A, Lasho TL, Finke C et al (2007) Prevalence and clinicopathological correlates of JAK exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 21: 1960-1963.
11. Barbui T, Carobbio A, Rambaldi A, Finazzi G (2009) Perspective on thrombosis in essential thrombocythemia and Polycythemia vera: is leukocytosis a causative factor? Blood 114: 759-763.
12. Landolfi R, Nicolazzi MA, Porfidia A, Di Gennaro L (2010) Polycythemia vera. Intern Emerg Med [Epub ahead of print].
13. Vannucchi AM (2009) Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med [Epub ahead of print].
14. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T (1998) No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 103: 772-777.